Rhythm Pharmaceuticals, Inc. develops and commercializes therapies for rare neuroendocrine diseases, centered on IMCIVREE (setmelanotide), an MC4R agonist for hyperphagia and severe obesity linked to rare MC4R pathway disorders. Company updates commonly cover U.S. and international commercialization of setmelanotide, regulatory authorizations and label expansions for acquired hypothalamic obesity, Bardet-Biedl syndrome, POMC/PCSK1 deficiency and LEPR deficiency, and safety information tied to approved uses.
Rhythm news also follows clinical data from setmelanotide studies, including acquired hypothalamic obesity and genetically caused MC4R pathway diseases, along with development of investigational MC4R agonists bivamelagon and RM-718 and preclinical small molecules for congenital hyperinsulinism. Recurring corporate items include financial results, specialty-pharmacy access arrangements, healthcare conference presentations and board governance changes.
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q1 2026 results and a business update on May 5, 2026. IMCIVREE generated $60.1M in global net product revenue; U.S. sales were $36.9M (61%) and international sales $23.2M (39%). FDA approved IMCIVREE for acquired hypothalamic obesity on March 19, 2026; European Commission authorized marketing for acquired HO; Japanese review is underway. Cash and short-term investments were $340.6M as of March 31, 2026. Non-GAAP operating expense guidance for 2026 is $385M–$415M.
Rhythm Pharmaceuticals (Nasdaq: RYTM) reported new pediatric data presented at the Pediatric Endocrine Society, showing longer-term setmelanotide outcomes in acquired hypothalamic obesity.
Highlights: in 10 pediatric patients completing 2.5 years, mean changes from baseline were BMI -16.4%, BMI Z-score -1.6, and %BMI95 -34.2 percentage points. Phase 3 TRANSCEND pediatric data after 1 year showed 71.1% improved ≥1 weight category.
Rhythm Pharmaceuticals (NASDAQ: RYTM) announced the European Commission authorized IMCIVREE (setmelanotide) for treatment of obesity and control of hunger in adults and children aged 4+ with acquired hypothalamic obesity.
The approval cites the Phase 3 TRANSCEND pivotal cohort (n=120): a statistically significant placebo-adjusted BMI reduction of -19.8%, with setmelanotide showing -16.5% mean BMI change versus +3.3% for placebo at 52 weeks (p<0.0001). Adult and pediatric subgroup placebo-adjusted BMI reductions were -19.2% and -20.2%, respectively. Common adverse events (>20%) included nausea, vomiting, diarrhea, injection site reaction, skin hyperpigmentation and headache. Commercial launches are anticipated in 2027; the U.S. sNDA was approved March 19, 2026.
Rhythm Pharmaceuticals (Nasdaq: RYTM) will report first quarter 2026 financial results on Tuesday, May 5, 2026 with a live conference call and webcast at 8:00 a.m. ET. The company also announced a fireside chat by CFO Hunter Smith at the Needham Virtual Healthcare Conference on April 16, 2026 at 11:00 a.m. ET.
Live webcasts for both events will be available in the Investor Relations "Events and Presentations" section at the company's investor website, with archived replays available approximately two hours after the earnings call and for 30 days after each event.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced Board changes on April 3, 2026: Kim Popovits was appointed director and Ed Mathers will depart.
Kim brings more than 40 years of life‑sciences leadership, including CEO and chairman roles at Genomic Health and senior commercialization roles at Genentech. Ed served on the Board since 2013.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced a positive CHMP opinion recommending expansion of IMCIVREE® (setmelanotide) to treat obesity and control hunger in adults and children aged 4+ with acquired hypothalamic obesity due to hypothalamic injury or impairment.
A final European Commission decision is anticipated in the second quarter of 2026; the CHMP opinion follows an FDA approval announced last week.
PANTHERx Rare was chosen by Rhythm Pharmaceuticals (Nasdaq: RYTM) as the exclusive U.S. specialty pharmacy for the expanded indication of IMCIVREE (setmelanotide) for adults and children aged 4 and older with acquired hypothalamic obesity, announced March 20, 2026.
PANTHERx will deploy its RxARECARE model for individualized case management, education, and financial and insurance navigation. PANTHERx has served as IMCIVREE's exclusive pharmacy for certain genetic obesity indications since 2020.
Rhythm Pharmaceuticals (NASDAQ: RYTM) announced FDA approval of IMCIVREE (setmelanotide) for acquired hypothalamic obesity (HO) in adults and pediatric patients aged 4 years and older. Approval was based on the Phase 3 TRANSCEND trial showing a -18.4% placebo-adjusted BMI reduction.
IMCIVREE is available immediately in the U.S.; Rhythm estimates ~10,000 people in the U.S. live with acquired HO. The company will host a conference call today at 7:00 p.m. ET.
Rhythm Pharmaceuticals (Nasdaq: RYTM) reported topline Phase 3 EMANATE results: the four genetic substudies did not meet prespecified primary endpoints for placebo-adjusted BMI change at Week 52.
Post hoc LOCF analyses showed statistically significant BMI reductions in POMC/PCSK1 Hets (−5.5%, p=0.0010) and SRC1 (NCOA1) (−6.2%, p<0.0001). No new safety signals were observed. A conference call was scheduled for 4:30 p.m. ET on March 16, 2026.
Rhythm Pharmaceuticals (Nasdaq: RYTM) reported additional positive 52-week data from its global Phase 3 TRANSCEND trial of setmelanotide in acquired hypothalamic obesity. Results showed a -18.8% placebo-adjusted BMI reduction (N=142) and mean BMI change of -16.4% on drug versus +2.4% on placebo (p<0.0001).
The dataset adds 12 Japanese patients and 10 supplemental patients. The company set a PDUFA goal date of March 20, 2026 for its supplemental NDA and will submit the final data package to the FDA on March 2, 2026. EMA CHMP opinion is anticipated in Q2 2026.